Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure
Evercore ISI downgraded Foghorn Therapeutics (FHTX) to In Line from Outperform, cutting its price target to $3.00 from $14.00 after the discontinuation of its lead clinical program, FHD-909. The stock is down 64% year-to-date, trading at $1.95. The firm removed FHD-909 from its model, reduced operating expenses, and estimates $131 million in net cash by year-end 2026. Other analysts have also adjusted their ratings and price targets following the drug program's halt.
How this was made
The 30-second read
Why it matters
The downgrade and trial failure are fresh, material news that likely trigger further sell‑offs.
Market read
Immediate negative impact on FHTX stock; potential ripple to peer biotech stocks.
What to watch
Potential cash runway of $150 M and remaining early‑stage programs could support a longer‑term rebound.
Background
The article reports a downgrade and trial discontinuation for Foghorn Therapeutics, a micro‑cap biotech.
Ticker impact
Evercore ISI downgraded Foghorn Therapeutics to In Line and cut its price target after the company discontinued its lead clinical program FHD-909 due to lack of efficacy.
downward pressure as investors price in the loss of the lead program
The lead drug was halted, analysts cut targets sharply, and the stock is already down 64% YTD, indicating further downside risk.
Market effects
Biotech sector may see broader risk aversion as trial failures raise concerns about similar programs.
US biotech investors likely to adjust exposure; limited impact outside the sector.
Minimal global effect beyond biotech investors.
Counterpoint
Some investors may view the lower valuation as a buying opportunity if the pipeline retains upside.
Key entities
- companyFoghorn Therapeutics
Biotech firm developing epigenetic degrader programs.
- analystEvercore ISI
Research firm that issued the downgrade.